Respiratory Dysbiosis in Preschool Children with Asthma: Predictive of a Severe Form
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age1-3
SponsorUniversity Hospital, Brest
About this trial
The prevalence of asthma in preschool children is between 11 and12%. Inhaled corticosteroid therapy is the main therapy used, however this treatment seems insufficiently effective in some children.
Recent research in cystic fibrosis has made it possible to highlight pulmotypes corresponding to the different stages of pulmonary dysbiosis, and a predictive microbiological signature of an increased risk of early primocolonization to P. aeruginosa. These pulmotypes are the result of the so-called "enterotyping" analysis, a biostatistical method that makes it possible to stratify individuals according to the analysis of the microbiota. In the light of these data, it seems interesting to transcribe the concept of using a biomarker of the microbiota in the monitoring of a chronic lung disease such as asthma.
The hypothesis is that there is respiratory dysbiosis causing corticosteroid resistance to treatment in children under 3 years of age with severe asthma.
Eligibility criteria
Qualifiers
Age greater than 1 year and less than 3 years
Diagnosis of asthma by a pediatrician
Parental consent
Affiliation to the social security system
Disqualifiers
Chronic pathologies: congenital heart disease, immune deficiency, cystic fibrosis, bronchopulmonary dysplasia, encephalopathy, primary ciliary dyskinesia, laryngomalacia, digestive pathology requiring digestive surgery
Premature < 34 SA
Recent antibiotic therapy (< 7 days)
Treatment with oral corticosteroid therapy within the previous 10 days.
Trial design
Treatments tested in this trial
- Stool test
- Blood test
- Induced sputum
- nasale virology
Treatment groups
30 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov